![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C16H19N5O4S |
Molar mass | 377.42 g·mol−1 |
3D model (JSmol) | |
| |
|
Selurampanel (INN, code nameBGG492) is adrug closely related to thequinoxalinedione series which acts as acompetitive antagonist of theAMPA andkainate receptors and, as of 2015, is being investigated inclinical trials byNovartis for the treatment ofepilepsy.[1][2][3] It has also been studied in the acute treatment ofmigraine, and was found to produce some pain relief, but with a relatively high rate ofside effects.[4]
![]() | Thisanticonvulsant-related article is astub. You can help Wikipedia byexpanding it. |